Immune cells protect our body against invading pathogens. The chemokine receptor CCR5 on the surface of T cells plays an important role in this process. However, CCR5 also is used by the HI-Virus as entrance gate into T cells. A research consortium led by the University of Basel has now deciphered the mechanism of CCR5 receptor activation. The study provides important insights for the development of effective treatments for AIDS, cancer and inflammatory diseases.
Scientists in a European collaboration propose a personalized protocol for optimizing stimulation of optic nerve fibers, for the blind, which takes into account feedback from the viewer's brain. The protocol has been tested on artificial neural networks known to simulate the physiology of the entire visual system, from the eye to the visual cortex. The stimulation protocol will be tested in clinical trials with partners in Rome.
Wissenschaftliche/r Assistent/in Mechatronik (60-80%) Hochschule Luzern - Technik & Architektur, Horw/Luzern
PhD position Soil Exotoxicology Fachhochschule Nordwestschweiz FHNW, Muttenz
Senior Scientific Researcher (80-100%) Hochschule Luzern, Rotkreuz
Doktorand/in FinTech / Investments (70-85%) Hochschule Luzern - Wirtschaft, Rotkreuz
Full Professor in Applied Economics University of Neuchâtel
Forschungsgruppenleiter/in Bodenqualität und Bodennutzung Agroscope, 8046 Zürich Affoltern ZH
Using the power of drawing to discern order in nature
Protection and promotion of native crayfish
How do immune cells get activated?
Updating the self-sufficiency ratio
New Imaging Center Pools the Know-How of Five EPFL Schools
Inventing sustainable solutions - one scientist's journey
Artificial intelligence speeds land-use classification
SDGs and USI. Health and Wellness
State Secretary Hirayama in Portugal to attend Africa-Europe Space Earth Observation High-Level Forum and hold bilateral talks
President Parmelin in Sweden for bilateral exchange
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
New Roche data for Evrysdi